Entries by Andrew Cann

June 2-4th, 2015 – 4th ISIRV-AVG Conference

4th ISIRV-AVG Conference Speaker: Dr. Carol Epstein, MediVector CMO, to speak on ‘The Clinical and Anti-Influenza Virus Effects of Favipiravir, a Novel Anti-RNA Virus, Anti-Influenza Agent’ http://www.isirv.org/site/index.php/special-interest-groups/antiviral-group-home/9-events/233-4th-isirv-avg-conference  

MediVector Completes Patient Enrollment in Two Phase 3 Studies of Favipiravir for Influenza

Boston, February 17, 2015 -More than 2,000 patients enrolled in the Americas, Europe, Australia, New Zealand and South Africa- MediVector, Inc. today announced it has successfully completed enrollment in two FAVOR favipiravir Phase 3 studies in adults with uncomplicated influenza (often called the “flu”).  The two studies enrolled 2,021 patients in participating clinics and practices […]

First Patient Enrolled in Northern Hemisphere for Phase 3 Study of Favipiravir for Influenza

BOSTON, Jan. 16, 2014 — MediVector, Inc. today announced the enrollment of its first patient in the United States in one of two FAVOR favipiravir Phase 3 studies in adults with uncomplicated influenza.  This multi-center, double-blind, placebo-controlled study is expected to enroll over 1,000 patients in participating clinics and practices in North, Central, and South America. “The […]